One Doctor Makes The Case For Human Trials
September 4, 2014 | KUOW
Marcie Sillman talks with Fred Hutchinson cancer researcher Dr. Jim Olson about the development of a new human drug-testing model.
Presage Biosciences – 2013 Fierce 15
September 24, 2013 | FierceBiotech
Treating Kids' Cancer With Science And A Pocket Full Of Hope
September 13, 2013 | National Public Radio (NPR) Morning Edition
NPR's Joe Palca visits with Jim Olson in a story that describes Dr. Olson's inspiration and hope for cancer treatment.
Device Tests Drugs on a Tumor That's Still in the Body
January 16, 2013 | MIT Technology Review
Presage’s device would allow oncologists to test potentially harmful compounds in tiny amounts before giving patients a full dose.
Comparing combos quickly
May 7, 2012 | BioCentury
Millennium Pharmaceuticals Inc. is using an in vivo screening platform from Presage Biosciences Inc. to speed up its preclinical characterization of cancer combination therapies. The platform enables simultaneous comparison of up to four treatments within a single tumor in a live mouse and could better predict efficacy than the in vitro assays that usually precede large-scale animal studies.
Presage Looks to Help Millennium Pick Cancer Drug Winners Early
April 6, 2012 | xconomy.com
Seattle-based Presage Biosciences, a spinoff from the Fred Hutchinson Cancer Research Center, is looking to help cancer drugmakers separate the winning compounds from the losers early in development, and now it’s found a major partner to put this idea to the test.
Millennium gets use of Presage drug combo technology
April 6, 2012 | Mass High Tech
Millennium: The Takeda Oncology Company has entered into a cancer research agreement with Presage Biosciences of Seattle, Wash., that gives the Cambridge biopharmaceutical company access to Presage’s technology for non-clinical identification of novel oncology drug combinations in solid tumors.
Presage Biosciences, Millennium to Partner on Cancer Drugs
April 6, 2012 | Science Business
Presage Biosciences, a biotechnology company in Seattle, and Millenium, a division of Takeda Pharmaceuticals in Cambridge, Massachusetts, say the two companies will collaborate on the development of new cancer therapies. Financial terms of the agreement were not disclosed.
Presage, a Hutch Spinoff, Raises $3M From Angels to Boost Cancer Drug Hit Rate
March 16, 2010 | xconomy.com
Seattle-based Presage Biosciences has a big dream for a biotech startup—and now it has seed capital to put that dream to the test...